贝伐单抗挽救治疗可延长复发性恶性脑胶质瘤患者的生存时间。
Bevacizumab rescue therapy extends the survival in patients with recurrent malignant glioma.
机构信息
Department of Oncology, Guangdong 999 Brain Hospital, Guangzhou 510510, China.
出版信息
Chin J Cancer Res. 2013 Apr;25(2):206-11. doi: 10.3978/j.issn.1000-9604.2013.03.10.
OBJECTIVE
We retrospectively studied the efficacy of bevacizumab as salvage therapy for recurrent malignant glioma with a focus on the overall survival (OS).
METHODS
Patients who received a therapy other than surgery for recurrent malignant glioma were included. Efficacy was evaluated using MRI. Neurological function was evaluated using the Response Assessment in Neuro-Oncology (RANO). The survival rate was calculated using the Kaplan-Meier method.
RESULTS
Fifty-one patients with recurrent glioma (31 grade III, 20 grade IV) were included. Among them, 22 subjects (43.1%) received bevacizumab. The median OS was 10.2 months (range, 1 to 27 months). Patients receiving bevacizumab had comparable OS (a median of 9.9 vs. 10.0 months) and similar 6-month survival rate (43% vs. 34%) to those who did not receive bevacizumab. A subgroup analysis failed to notice any significant difference in grade III glioma patients receiving bevacizumab vs. those who did not. The median survival was significantly longer at 8.9 months (range, 4 to 13 months) in grade IV glioma patients receiving bevacizumab than in those who did not (5.6 months, range, 2 to 7 months, P=0.042). The 6-month survival rate was higher (83%) in those who received bevacizumab than in those who did not (47%, P=0.046). No grade 3/4 adverse events were observed in any patient.
CONCLUSIONS
Bevacizumab, as a rescue therapy, provides a survival benefit for recurrent grade IV glioma.
目的
我们回顾性研究了贝伐珠单抗作为复发性恶性胶质瘤挽救治疗的疗效，重点关注总生存期（OS）。
方法
纳入接受手术以外的治疗方案治疗复发性恶性胶质瘤的患者。采用 MRI 评估疗效，采用 RANO（神经肿瘤反应评估）评估神经功能。采用 Kaplan-Meier 法计算生存率。
结果
共纳入 51 例复发性胶质瘤患者（31 级 3 级，20 级 4 级），其中 22 例（43.1%）接受贝伐珠单抗治疗。中位 OS 为 10.2 个月（范围 1-27 个月）。接受贝伐珠单抗治疗的患者 OS 相当（中位 9.9 个月 vs. 10.0 个月），6 个月生存率相似（43% vs. 34%）。亚组分析未发现 3 级胶质瘤患者接受贝伐珠单抗与未接受贝伐珠单抗的患者有显著差异。接受贝伐珠单抗治疗的 4 级胶质瘤患者中位生存时间明显长于未接受贝伐珠单抗的患者（8.9 个月，范围 4-13 个月 vs. 5.6 个月，范围 2-7 个月，P=0.042）。接受贝伐珠单抗治疗的患者 6 个月生存率较高（83%），未接受贝伐珠单抗治疗的患者为 47%（P=0.046）。任何患者均未观察到 3/4 级不良事件。
结论
贝伐珠单抗作为挽救治疗，可为复发性 4 级胶质瘤患者提供生存获益。
Zotero 插件